Skip to main content

Table 3 Changes in safety parameters

From: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Parameter n Baseline LOCF p-value
Body mass index (kg/m2) 362 25.49 ± 3.72 25.40 ± 3.77 0.087
Total bilirubin (mg/dL) 292 0.64 ± 0.25 0.58 ± 0.22 <0.001
Creatinine (mg/dL) 449 0.76 ± 0.17 0.78 ± 0.19 <0.001
Blood urea nitrogen (mg/dL) 392 15.30 ± 3.92 16.35 ± 4.84 <0.001
AST (IU/L) 479 30.8 ± 19.7 28.8 ± 15.1 0.007
ALT (IU/L) 479 31.9 ± 28.2 26.8 ± 21.3 <0.001
GGT (IU/L) 451 66.1 ± 96.1 48.4 ± 69.6 <0.001
ALP (IU/L) 309 224.1 ± 87.9 184.7 ± 67.5 <0.001
CPK (mg/dL) 301 127.8 ± 82.9 132.0 ± 95.6 0.416
SBP (mmHg) 489 130.4 ± 13.5 128.6 ± 12.4 0.002
DBP (mmHg) 486 76.0 ± 9.5 74.8 ± 8.8 0.004
HbA1c (%) 308 6.46 ± 1.41 6.39 ± 1.29 0.187
  1. Data are expressed as mean ± standard deviation safety parameters from baseline to LOCF. The paired t test was used to examine the significance of within-group changes. LOCF: last observation carried forward; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase; ALP: alkaline phosphatase; CPK: creatine phosphokinase; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin.